FORT WASHINGTON, Pa., Feb. 27, 2017 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it plans to participate at the following upcoming investor conferences.
About Impax Laboratories, Inc.Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.
Company Contacts: Mark DonohueInvestor Relations and Corporate Communications (215) 558-4526 www.impaxlabs.com
Logo - http://photos.prnewswire.com/prnh/20150310/180590LOGO
Advertisement
- Raymond James and Associates' 38th Annual Institutional Investors Conference at 11:35 a.m. ET on March 6, 2017 in Orlando, FL.
- Cowen and Company 37th Annual Health Care Conference at 8:00 a.m. ET on March 7, 2017 in Boston, MA.
- Barclays Global Healthcare Conference at 8:30 a.m.ET on March 16, 2017 in Miami, FL.
Advertisement
About Impax Laboratories, Inc.Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.
Company Contacts: Mark DonohueInvestor Relations and Corporate Communications (215) 558-4526 www.impaxlabs.com
Logo - http://photos.prnewswire.com/prnh/20150310/180590LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/impax-to-present-at-upcoming-investor-conferences-300413847.html
SOURCE Impax Laboratories, Inc.
